Prostate Cancer Reports
54

Volume 5 Supplement 12
December 2017


Home > Prostate Cancer Reports > Volume 5, Year 2017 > Supplement 12, December



CONTENTS



DIAGNOSIS
EPIDEMIOLOGY, RISK FACTORS, PREVENTION
ETIOLOGY, PATHOGENESIS, PATHOLOGY
FOLLOW-UP, QUALITY OF LIFE
INTEGRATIVE MEDICINE
OVERALL MANAGEMENT
PROGNOSIS
TREATMENT



DIAGNOSIS



Calais J, Czernin J, Cao M, Kishan AU, Hegde JV, Shaverdian N, Sandler KA, Chu FI, King CR, Steinberg ML, Rausher I, Schmidt-Hegemann NS, Poeppel T, Hetkamp P, Ceci F, Herrmann K, Fendler WP, Eiber M, Nickols NG.
68Ga-PSMA PET/CT mapping of prostate cancer biochemical recurrence following radical prostatectomy in 270 patients with PSA<1.0ng/ml: Impact on Salvage Radiotherapy Planning.
J Nucl Med. 2017 Nov 9. pii: jnumed.117.201749. doi: 10.2967/jnumed.117.201749. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Chaloupka M, Herlemann A, D'Anastasi M, Cyran CC, Ilhan H, Gratzke C, Stief CG.
68Gallium-Prostate-Specific Membrane Antigen PET/Computed Tomography for Primary and Secondary Staging in Prostate Cancer.
Urol Clin North Am. 2017 Nov;44(4):557-563. doi: 10.1016/j.ucl.2017.07.004.
Source | Abstract | Full text | Similar articles




Fusco R, Sansone M, Granata V, Setola SV, Petrillo A.
A systematic review on multiparametric MR imaging in prostate cancer detection.
Infect Agent Cancer. 2017 Oct 30;12:57. doi: 10.1186/s13027-017-0168-z. eCollection 2017.
Source | Abstract | Full text | Similar articles




Giovacchini G, Giovannini E, Riondato M, Ciarmiello A.
PET/CT with 68Ga-PSMA in prostate cancer: radiopharmaceutical background and clinical implications.
Curr Radiopharm. 2017 Nov 1. doi: 10.2174/1874471010666171101121803. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Halpern JA, Oromendia C, Shoag JE, Mittal S, Cosiano MF, Ballman KV, Vickers AJ, Hu JC.
Utility of Digital Rectal Examination (DRE) as an Adjunct to Prostate Specific Antigen (PSA) in the Detection of Clinically Significant Prostate Cancer.
J Urol. 2017 Oct 20. pii: S0022-5347(17)77762-2. doi: 10.1016/j.juro.2017.10.021. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Henkenberens C, Derlin T, Bengel FM, Ross TL, Wester HJ, Hueper K, Kuczyk MA, Christiansen H, von Klot CA.
Patterns of relapse as determined by 68Ga-PSMA ligand PET/CT after radical prostatectomy : Importance for tailoring and individualizing treatment.
Strahlenther Onkol. 2017 Nov 13. doi: 10.1007/s00066-017-1231-9. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Kato M, Kimura K, Hirakawa A, Kobayashi Y, Ishida R, Kamihira O, Majima T, Funahashi Y, Sassa N, Matsukawa Y, Hattori R, Gotoh M, Tsuzuki T.
Prognostic parameter for high risk prostate cancer patients at initial presentation.
Prostate. 2017 Nov 2. doi: 10.1002/pros.23438. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Lorca AM.
Management of biochemically recurrent prostate cancer: molecular imaging perspective.
World J Urol. 2017 Nov 13. doi: 10.1007/s00345-017-2127-0. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Paddubny K, Freitag MT, Kratochwil C, Koerber S, Radtke JP, Sakovich R, Kopka K, Giesel FL.
Fluorine-18 Prostate-specific Membrane Antigen-1007 Positron Emission Tomography/Computed Tomography and Multiparametric Magnetic Resonance Imaging in Diagnostics of Local Recurrence in a Prostate Cancer Patient After Recent Radical Prostatectomy.
Clin Genitourin Cancer. 2017 Oct 5. pii: S1558-7673(17)30304-X. doi: 10.1016/j.clgc.2017.09.014. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Rowe SP, Pienta KJ, Pomper MG, Gorin MA.
PSMA-RADS Version 1.0: A Step Towards Standardizing the Interpretation and Reporting of PSMA-targeted PET Imaging Studies.
Eur Urol. 2017 Nov 10. pii: S0302-2838(17)30962-4. doi: 10.1016/j.eururo.2017.10.027. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Schmidt-Hegemann NS, Fendler WP, Buchner A, Stief C, Rogowski P, Niyazi M, Eze C, Li M, Bartenstein P, Belka C, Ganswindt U.
Detection level and pattern of positive lesions using PSMA PET/CT for staging prior to radiation therapy.
Radiat Oncol. 2017 Nov 10;12(1):176. doi: 10.1186/s13014-017-0902-0.
Source | Abstract | Full text | Similar articles




Schmidkonz C, Hollweg C, Beck M, Reinfelder J, Goetz TI, Sanders JC, Schmidt D, Prante O, Bäuerle T, Cavallaro A, Uder M, Wullich B, Goebell P, Kuwert T, Ritt P.
99m Tc-MIP-1404-SPECT/CT for the detection of PSMA-positive lesions in 225 patients with biochemical recurrence of prostate cancer.
Prostate. 2017 Nov 6. doi: 10.1002/pros.23444. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Sheridan AD, Nath SK, Syed JS, Aneja S, Sprenkle PC, Weinreb JC, Spektor M.
Risk of Clinically Significant Prostate Cancer Associated With Prostate Imaging Reporting and Data System Category 3 (Equivocal) Lesions Identified on Multiparametric Prostate MRI.
AJR Am J Roentgenol. 2017 Nov 7:1-11. doi: 10.2214/AJR.17.18516. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Tan N, Shen L, Khoshnoodi P, Alcalá HE, Yu W, Hsu W, Reiter RE, Lu DY, Raman SS.
Pathological and 3 Tesla Volumetric MR Predictors of Biochemical Recurrence after Robotic Assisted Radical Prostatectomy: Correlation with Whole Mount Histopathology.
J Urol. 2017 Nov 8. pii: S0022-5347(17)77848-2. doi: 10.1016/j.juro.2017.10.042. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Zacho HD, Nielsen JB, Haberkorn U, Stenholt L, Petersen LJ.
68 Ga-PSMA PET/CT for the detection of bone metastases in prostate cancer: a systematic review of the published literature.
Clin Physiol Funct Imaging. 2017 Oct 29. doi: 10.1111/cpf.12480. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Xiao WJ, Zhu Y, Dai B, Ye DW.
Evaluation of the major changes in eighth edition of the American Joint Committee on Cancer pathological staging for prostate cancer treated with prostatectomy.
PLoS One. 2017 Nov 9;12(11):e0187887. doi: 10.1371/journal.pone.0187887. eCollection 2017.
Source | Abstract | Full text | Similar articles



EPIDEMIOLOGY, RISK FACTORS, PREVENTION



Kang M, Ku JH, Kwak C, Kim HH, Jeong CW.
Effects of Aspirin, Nonsteroidal Anti-inflammatory Drugs, Statin and COX2 Inhibitor on the Developments of Urological Malignancies: A Population-Based Study with 10-Year Follow-up Data in Korea.
Cancer Res Treat. 2017 Oct 27. doi: 10.4143/crt.2017.248. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



ETIOLOGY, PATHOGENESIS, PATHOLOGY



Assel M, Dahlin A, Ulmert D, Bergh A, Stattin P, Lilja H, Vickers AJ.
Association Between Lead Time and Prostate Cancer Grade: Evidence of Grade Progression from Long-term Follow-up of Large Population-based Cohorts Not Subject to Prostate-specific Antigen Screening.
Eur Urol. 2017 Oct 21. pii: S0302-2838(17)30860-6. doi: 10.1016/j.eururo.2017.10.004. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



FOLLOW-UP, QUALITY OF LIFE



Clavell-Hernández J, Martin C, Wang R.
Orgasmic Dysfunction Following Radical Prostatectomy: Review of Current Literature.
Sex Med Rev. 2017 Nov 3. pii: S2050-0521(17)30120-8. doi: 10.1016/j.sxmr.2017.09.003. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



INTEGRATIVE MEDICINE



Lin PH, Aronson W, Freedland SJ.
An update of research evidence on nutrition and prostate cancer.
Urol Oncol. 2017 Nov 2. pii: S1078-1439(17)30536-7. doi: 10.1016/j.urolonc.2017.10.006. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



OVERALL MANAGEMENT



Bjurlin MA, Taneja SS.
Prostate Cancer.
Urol Clin North Am. 2017 Nov;44(4):xv-xvi. doi: 10.1016/j.ucl.2017.08.001.
Source | Abstract | Full text | Similar articles




Campobasso D, Prati G, Frattini A.
Very high-risk prostate cancer: multimodality treatment will be the new frontier.
Cent European J Urol. 2017;70(3):324-325. doi: 10.5173/ceju.2017.1535. Epub 2017 Aug 16.
Source | Abstract | Full text | Similar articles




Damodaran S, Kyriakopoulos CE, Jarrard DF.
Newly Diagnosed Metastatic Prostate Cancer: Has the Paradigm Changed?
Urol Clin North Am. 2017 Nov;44(4):611-621. doi: 10.1016/j.ucl.2017.07.008.
Source | Abstract | Full text | Similar articles




Klotz L.
Contemporary Active Surveillance: Candidate Selection, Follow-up Tools, and Expected Outcomes.
Urol Clin North Am. 2017 Nov;44(4):565-574. doi: 10.1016/j.ucl.2017.07.005.
Source | Abstract | Full text | Similar articles




Mossanen M, Krasnow RE, Nguyen PL, Trinh QD, Preston M, Kibel AS.
Approach to the Patient with High-Risk Prostate Cancer.
Urol Clin North Am. 2017 Nov;44(4):635-645. doi: 10.1016/j.ucl.2017.07.009.
Source | Abstract | Full text | Similar articles




Mottet N, De Santis M, Briers E, Bourke L, Gillessen S, Grummet JP, Lam TB, van der Poel HG, Rouvière O, van den Bergh RCN, Cornford P.
Updated Guidelines for Metastatic Hormone-sensitive Prostate Cancer: Abiraterone Acetate Combined with Castration Is Another Standard.
Eur Urol. 2017 Nov 2. pii: S0302-2838(17)30839-4. doi: 10.1016/j.eururo.2017.09.029. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Nair R, Lamb BW, Geurts N, Alghazo O, Lam W, Lawrentschuk N, Murphy DG.
The Role of Local Therapy for Oligometastatic Prostate Cancer: Should We Expect a Cure?
Urol Clin North Am. 2017 Nov;44(4):623-633. doi: 10.1016/j.ucl.2017.07.013.
Source | Abstract | Full text | Similar articles




Sumanasuriya S, De Bono J.
Treatment of Advanced Prostate Cancer-A Review of Current Therapies and Future Promise.
Cold Spring Harb Perspect Med. 2017 Nov 3. pii: a030635. doi: 10.1101/cshperspect.a030635. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



PROGNOSIS



Leyh-Bannurah SR, Dell'Oglio P, Zaffuto E, Briganti A, Schiffmann J, Pompe RS, Tilki D, Heinzer H, Graefen M, Karakiewicz PI, Budäus L.
Assessment of Oncological Outcomes After Radical Prostatectomy According to Preoperative and Postoperative Cancer of the Prostate Risk Assessment Scores: Results from a Large, Two-center Experience.
Eur Urol Focus. 2017 Nov 9. pii: S2405-4569(17)30255-9. doi: 10.1016/j.euf.2017.10.015. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Seyedin SN, Mitchell DL, Mott SL, Russo JK, Tracy CR, Snow AN, Parkhurst JR, Smith MC, Buatti JM, Watkins JM.
Is More Always Better? An Assessment of the Impact of Lymph Node Yield on Outcome for Clinically Localized Prostate Cancer with Low/Intermediate Risk Pathology (pT2-3a/pN0) Managed with Prostatectomy Alone.
Pathol Oncol Res. 2017 Oct 27. doi: 10.1007/s12253-017-0349-5. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Whalen MJ, Pak JS, Lascano D, Ahlborn D, Matulay JT, McKiernan JM, Benson MC, Wenske S.
Oncologic Outcomes of Definitive Treatments for Low- and Intermediate-Risk Prostate Cancer After a Period of Active Surveillance.
Clin Genitourin Cancer. 2017 Oct 16. pii: S1558-7673(17)30313-0. doi: 10.1016/j.clgc.2017.10.007. [Epub ahead of print]
Source | Abstract | Full text | Similar articles



TREATMENT



Edison E, Tariq Shah T, Ahmed HU.
Focal Ablation of Early-Stage Prostate Cancer: Candidate Selection, Treatment Guidance, and Assessment of Outcome.
Urol Clin North Am. 2017 Nov;44(4):575-585. doi: 10.1016/j.ucl.2017.07.006.
Source | Abstract | Full text | Similar articles




Ganzer R, Hadaschik B, Pahernik S, Koch D, Baumunk D, Kuru T, Heidenreich A, Stolzenburg JU, Schostak M, Blana A.
Prospective multicenter Phase II-Study on focal therapy (hemiablation) of the prostate with High Intensity focused ultrasound (HIFU).
J Urol. 2017 Oct 26. pii: S0022-5347(17)77795-6. doi: 10.1016/j.juro.2017.10.033. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Ghadjar P, Wiegel T.
Re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.06.027.
Eur Urol. 2017 Oct 19. pii: S0302-2838(17)30861-8. doi: 10.1016/j.eururo.2017.10.005. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Kobayashi T, Kanao K, Araki M, Terada N, Kobayashi Y, Sawada A, Inoue T, Ebara S, Watanabe T, Kamba T, Sumitomo M, Nasu Y, Ogawa O.
Impact of a robotic surgical system on treatment choice for men with clinically organ-confined prostate cancer.
Int J Clin Oncol. 2017 Nov 11. doi: 10.1007/s10147-017-1203-1. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Ramey SJ, Agrawal S, Abramowitz MC, Moghanaki D, Pisansky TM, Efstathiou JA, Michalski JM, Spratt DE, Hearn JWD, Koontz BF, Liauw SL, Pollack A, Anscher MS, Den RB, Stephans KL, Zietman AL, Lee WR, Stephenson AJ, Tendulkar RD.
Multi-institutional Evaluation of Elective Nodal Irradiation and/or Androgen Deprivation Therapy with Postprostatectomy Salvage Radiotherapy for Prostate Cancer.
Eur Urol. 2017 Nov 8. pii: S0302-2838(17)30900-4. doi: 10.1016/j.eururo.2017.10.009. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Spratt DE, Dess RT, Feng FY.
Reply to Pirus Ghadjar and Thomas Wiegel's Letter to the Editor re: Daniel E. Spratt, Robert T. Dess, Zachary S. Zumsteg, et al. A Systematic Review and Framework for the Use of Hormone Therapy with Salvage Radiation Therapy for Recurrent Prostate Cancer. Eur Urol. In press. http://dx.doi.org/10.1016/j.eururo.2017.06.027: Salvage Radiotherapy and Hormone Therapy: Change Is Coming, Just Not Quite Yet.
Eur Urol. 2017 Oct 27. pii: S0302-2838(17)30897-7. doi: 10.1016/j.eururo.2017.10.006. [Epub ahead of print]
Source | Abstract | Full text | Similar articles




Zhong W, Smith B, Haghighi K, Mancuso P.
Systematic Review of Decision Aids for the Management of Men with Localized Prostate Cancer.
Urology. 2017 Oct 31. pii: S0090-4295(17)31154-8. doi: 10.1016/j.urology.2017.10.022. [Epub ahead of print]
Source | Abstract | Full text | Similar articles